PHOTO ESSAY: Behind-the-scenes moments as hail chasers learn about pounding and costly storms
MORTON, Texas — Even when Mother Nature turns nasty, the weather extremes carry a sense of awesome beauty. About 60 scientists this spring and early summer went straight into hailstorms to better understand what makes them tick and learn how to reduce the $10 billion in annual in damage they cause each year in the United States.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Ultima Genomics Selected to Support the World's Largest Proteomics Studies to Date Led by Regeneron Genetics Center
FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing platform has been selected to support Regeneron Genetics Center® (RGC™) and its recently launched U.S. large-scale proteomics study. The study, comprised of 200,000 blood serum samples secured by RGC from its long-standing research collaboration with Geisinger Health System, will be combined with the recently announced UK Biobank Pharma Proteomics Project, the largest proteomics study undertaken to date, which will also utilize Ultima's UG 100 sequencing platform for the analysis of 600,000 samples from UK consented participants. Combined, these studies reflect the growing role of high-throughput, cost-efficient sequencing in enabling large-scale counting applications across proteomics and other emerging omics fields. For these efforts, RGC will utilize the Olink Explore HT platform and Ultima's UG 100 platform. Ultima's technology was selected for its scalability, efficiency, and suitability for large population-level studies requiring high-throughput data generation. "We are pleased to continue supporting the ever-expanding large-scale proteomics studies that have the potential to drive important scientific and clinical insights," said Gilad Almogy, founder and CEO of Ultima Genomics. "These RGC proteomics studies build on the growing momentum we are seeing for population-scale proteomics and counting applications powered by Ultima's sequencing platform." About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit Ultima Media ContactVikki Herrera408-206-7009vikki@ View original content to download multimedia: SOURCE Ultima Genomics
Gizmodo
an hour ago
- Gizmodo
New Images Show Andromeda Galaxy as You've Never Seen It Before
Andromeda lies 2.5 million light-years away from the Milky Way, a spiral galaxy similar to our own that has allowed scientists to better understand our galactic home. A new composite image reveals our closest galactic neighbor in five different wavelengths of light, combined together to create a stunningly detailed view of Andromeda. Telescopes capture images in different wavelengths by observing a specific part of the electromagnetic spectrum, from low-frequency radio waves to extremely high-frequency gamma rays. By using different wavelengths, astronomers are able to see far more of the cosmos, whether it be glowing dust and stars or colliding galaxies. For the latest image of Andromeda, also known as M31, astronomers featured X-ray data from NASA's Chandra Observatory, revealing the high-energy radiation around the supermassive black hole at the center of the galaxy. The X-ray data, captured by the European Space Agency's XMM-Newton, is shown in red, green, and blue. Ultraviolet data from NASA's retired GALEX is in blue; infrared data from NASA's retired Spitzer Space Telescope, the Infrared Astronomy Satellite, COBE, Planck, and Herschel is in red, orange, and purple; and radio data from the Westerbork Synthesis Radio Telescope is in red-orange, according to NASA. Astrophotographers Jakob Sahner and Tarun Kottary provided some optical data using ground-based telescopes. Andromeda is a classic spiral, with graceful arms that rotate around a central bulge. It stretches across 220,000 light-years, twice the size of the Milky Way. The two galaxies are on an unfortunate collision course with one another and are expected to merge in about 4.5 billion years. Or maybe not, as research published earlier this month suggested. Astronomers also converted the multi-wavelength data to sound, creating a beautiful tune from Andromeda's dust lanes and star clusters. To create Andromeda's new song, scientists separated the layers captured by each telescope and stacked them on top of each other horizontally, beginning with X-rays at the top and then moving through ultraviolet, optical, infrared, and radio at the bottom. Each type of light is mapped to a different range of notes, from lower-energy radio waves all the way through the high energy of X-rays. The brightness of each source controls the volume of the galactic song, and the vertical location dictates the pitch. The latest composite image of Andromeda was released in honor of legendary astronomer Vera Rubin, who discovered evidence for dark matter by measuring the velocity of stars in the spiral galaxy. In the 1960s, Rubin carefully observed Andromeda and determined that unseen matter was affecting how the galaxy's spiral arms rotated. Earlier this week, the Vera C. Rubin Observatory, named after the pioneering astronomer, released its very first images of the cosmos.
Yahoo
an hour ago
- Yahoo
Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas
PARIS, June 26, 2025--(BUSINESS WIRE)--Orano Med, a subsidiary of the Orano Group and a pioneer in radioligand therapies in oncology, today inaugurated the expansion of its main Research and Development Center located in Plano, Texas (USA). This strategic facility is dedicated to developing novel radiopharmaceuticals and conducting preclinical research focused on targeted alpha therapies using lead-212 (212Pb), an innovative and promising approach against various types of cancer. The site hosts the R&D teams of Orano Med as well as those of its subsidiary Macrocyclics, a manufacturer of customized chelating agents. With an investment of over $5 million, Orano Med has expanded its R&D Center by approximately 11,000 ft². The expansion includes around 5,000 ft² of new laboratory space, enabling the advancement of a growing pipeline and doubling the Good Manufacturing Practice (GMP) production capacity for early clinical trial supply. In addition, about 5,500 ft² of new office space has been added to accommodate the site's growing team, whose headcount has doubled over the past four years. Overall, this represents about a 50% increase in space compared to the pre-existing facility. Julien Torgue, Chief Scientific Officer of Orano Med, stated: "The expansion of our R&D center enhances our ability to develop lead-212-based radioligand therapies by giving our teams the resources they need to advance a growing pipeline of drug candidates through to the clinic. With an integrated platform, cutting-edge equipment and a focused scientific strategy, we are well positioned to support both our internal developments and collaborations with partners." Orano Med's R&D platform is fully integrated, combining cutting-edge equipment and a highly experienced team to advance the development of next-generation cancer therapies. The company can carry out the full range of preclinical development studies, including in vivo and Chemistry, Manufacturing and Controls (CMC) studies, onsite. Orano Med conducts both in-house research programs and collaborative developments with biotech and pharmaceutical partners. This integrated approach ensures a rapid and reliable transition from research to clinical phases. While the primary mission of the research and development center is therapeutic development, the facility also serves as production hub for lead-212 based drug candidates for early-stage clinical trials in the U.S. This expansion demonstrates Orano Med's strong commitment to innovation and leadership in the field of radioligand therapies, accelerating the development of new treatment options for patients worldwide. A celebration was held on-site with local teams and Orano Med's Executive Committee to mark this important milestone. During the event, Orano Med also unveiled the new name of the facility: Drug Development and Preclinical Unit (DDPU) – George de Hevesy Center Arnaud Lesegretain, President and Chief Executive Officer of Orano Med, added: "This expansion marks an important step in Orano Med's growth at our Plano site, which has played a key role since the inception of the company 15 years ago. It reinforces our world-class R&D capabilities in the U.S. and strengthens our ability to deliver innovative targeted alpha therapies by supporting early-stage development in a fully integrated environment." About Orano Med Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). AlphaMedix, its most advanced asset in clinical development for GEP-NETs tumors, received Breakthrough Designation from the FDA in 2024. The company is advancing several potential treatments using 212Pb combined with various targeting agents through clinical and preclinical studies. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US. It is expanding its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe and building a unique, independent, and fully integrated industrial platform to serve the needs of patients globally. For more information, please visit: About Orano As a recognized international leading operator in the field of nuclear materials, Orano delivers solutions to address present and future global energy and health challenges. Its expertise and mastery of cutting-edge technologies enable Orano to offer its customers high value-added products and services throughout the entire fuel cycle. Every day, the Orano group's 17,500 employees draw on their skills, unwavering dedication to safety and constant quest for innovation, with the commitment to develop know-how in the transformation and control of nuclear materials, for the climate and for a healthy and resource-efficient world, now and tomorrow. Orano, giving nuclear energy its full value. About Targeted Alpha Therapy Targeted alpha therapy (TAT) relies on a simple concept: combining the ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha-emitting radioisotopes. Alpha decay consists of the emission of a helium nucleus (alpha particle) together with very high linear energy transfer and a range emission of only few cell layers, resulting in irreparable double strand DNA breaks in cells adjacent only to area of alpha emission. This approach results in an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. As a result, alpha emitters are considered as the most powerful payloads to be found for targeted therapies. View source version on Contacts Mike SinclairHalsin Partnersmsinclair@
